Naurex, Inc, an affiliate of Allergan
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Naurex, Inc, an affiliate of Allergan sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Naurex, Inc, an affiliate of Allergan: 18 sponsored US clinical trials, none currently recruiting.
Naurex, Inc, an affiliate of Allergan sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 8 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Human Abuse Potential, with 1 trials.
Top-decile sponsor footprint
Naurex, Inc, an affiliate of Allergan ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Assessment of Effect of Rapastinel on Driving Performance
NCT03814733
Assessment of Abuse Potential of Rapastinel in Humans
NCT03799900
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
NCT03668600
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
NCT03614156
Study of Rapastinel as Monotherapy in Patients With MDD
NCT03560518
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
NCT03352453
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT03002077
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
NCT02951988
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
NCT02943577
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
NCT02943564
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
NCT02932943
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
NCT02366364
Open Label Extension for GLYX13-C-202, NCT01684163
NCT02192099
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
NCT02067793
Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers
NCT01856556
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
NCT01684163
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
NCT01234558
Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers
NCT01014650
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 8 |
Therapeutic Areas
How the Naurex, Inc, an affiliate of Allergan archive is shaped
18 indexed studies, none listed as recruiting (0% open); 13 completed (72%).
Phase mix: 8 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Human Abuse Potential (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Naurex, Inc, an affiliate of Allergan: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Naurex, Inc, an affiliate of Allergan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Naurex, Inc, an affiliate of Allergan page
18 registered trials is a research-attention snapshot, not an endorsement of Naurex, Inc, an affiliate of Allergan or any single study.
- None of Naurex, Inc, an affiliate of Allergan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Human Abuse Potential is the condition Naurex, Inc, an affiliate of Allergan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Human Abuse Potential trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Naurex, Inc, an affiliate of Allergan pipeline card: 18 registered trials from official public datasets.Report a data error.